Opendata, web and dolomites

DECODE SIGNED

reDucing the health and Economic COst of Diagnostic uncErtainty: launch and randomized control trial of the first validated bacterial versus viral test

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DECODE project word cloud

Explore the words cloud of the DECODE project. It provides you a very rough idea of what is the project "DECODE" about.

workflow    inferior    data    distinguishing    global    expand    settings    infection    decide    inappropriate    blood    antimicrobial    500    efforts    confidence    runs    care    trade    acute    pioneering    clinical    clinically    samples    outcomes    clinician    validation    reduces    blind    capillary    leads    healthcare    fight    amr    share    gaps    regulatory    conduct    routinely    instances    market    release    trial    decode    enrolling    cleared    double    broad    reducing    economic    dach    decodes    serum    indistinguishable    solution    bv    biomarkers    elevated    thousands    threats    children    suitable    commercially    validated    superiority    clinicians    viral    hospitalization    misuse    resistance    burden    diagnostic    diagnostics    gather    world    concurrently    immune    initiate    demonstrated    memed    body    tool    primary    compatible    patient    bacterial    risk    rct    health    externally    avoidable    minutes    routine    platform    patients    complete    poc    multicentre    constraints    suspected    15    key    infections    actionable    randomized    utility    applicability    problem    gap   

Project "DECODE" data sheet

The following table provides information about the project.

Coordinator
MEMED DIAGNOSTICS LTD 

Organization address
address: NAHUM HETH STREET 5
city: TIRAT CARMEL
postcode: 39120
website: www.me-med.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙571˙427 €
 EC max contribution 2˙499˙999 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEMED DIAGNOSTICS LTD IL (TIRAT CARMEL) coordinator 2˙499˙999.00

Map

 Project objective

Problem: Clinicians routinely face diagnostic uncertainty because acute infections are often clinically indistinguishable and today’s diagnostics have constraints. This uncertainty leads to inappropriate patient management, including antimicrobial misuse and avoidable hospitalization. The associated health economic burden are inferior patient outcomes, elevated costs, and antimicrobial resistance (AMR), one of the top 10 threats to global health. Potential solution: In many instances, the clinician only needs to know with confidence if the infection is bacterial or viral to decide how to manage a patient suspected to have an acute infection. We have developed and validated MeMed BV™ - a pioneering test for distinguishing between bacterial and viral infections that decodes the body’s immune response to infection. BV™ has been both double-blind and externally validated in clinical studies enrolling thousands of patients and demonstrated superiority to biomarkers in routine use. Concurrently, we have developed Key™, an easy-to-use POC platform that runs BV™ in 15 minutes. Gap: Broad impact of BV™ and market share require high-risk efforts to address the following major gaps: 1. Real world evidence of usage and impact on workflow. 2. Validation of clinical utility in a randomized control trial (RCT). 3. Expand applicability to primary care settings. Proposed objectives: 1. To initiate market release in DACH and gather real world data. 2. To conduct a multicentre RCT enrolling 500 children. 3. Complete development of BV™ compatible with capillary blood. Impact: DECODE will take BV™ on Key™ from a test regulatory cleared for use to one that is available commercially and adopted in routine care, has validated clinical utility and is suitable for both serum and capillary blood samples. By providing an actionable tool that reduces diagnostic uncertainty, this project will improve patient outcomes while reducing healthcare costs and help fight AMR.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DECODE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DECODE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More